In a significant move to address chronic kidney disease (CKD) complications, Zydus Lifesciences has announced a collaborative research agreement with the Lucknow-based CSIR-Central Drug Research Institute (CDRI) to develop an innovative oral medication targeting chronic kidney disease-induced osteoporosis. The partnership will focus on discovering small molecule
Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) to market Scopolamine Transdermal System 1 mg/3 days. (USRLD: Transderm Scop Transdermal System ® 1 mg/3 days). This is the
Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) today announced that the Mexican regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk), has granted marketing approval for MamitraTM, a Trastuzumab biosimilar. The drug will be marketed in different strengths
Need to harmonize traditional and modern medicine to combat alarming health problems: Sarbananda Sonowal Investment in Digital Technology to Extend India's Services Through Telemedicine: Dr Tedros Adhanom Ghebreyesus, Director General, WHO Dr Mansukh Mandaviya, Minister of Health and Family Welfare, Govt of India today said that India
Four Posters accepted at The Liver Meeting® 2022 Two Posters are awarded the “AASLD Presidential Poster Of Distinction” Ahmedabad, India November 03, 2022 Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), a discovery-driven, global lifesciences company today announced that four abstracts on Saroglitazar Mg will be
